“Co-ordinated effort” needed to unlock cannabis crop benefits

Unlocking the full potential of cannabis for agriculture and human health will require a co-ordinated scientific effort to assemble and map the cannabis genome, says an international study led by Canadian researchers. 

In a statistical analysis of existing data and studies led by the University of Saskatchewan, the authors conclude there are large gaps in the scientific knowledge of this high-demand, multi-purpose crop. 

“Considering the importance of genomics in the development of any crop, this analysis underlines the need for a co-ordinated effort to quantify the genetic and biochemical diversity of this species,” the authors state.

The team, which includes scientists in The Netherlands, Germany, and the US, found that less than 50 per cent of the cannabis genome is accurately mapped, with about 10 per cent of the genome missing and another 10 to 25 per cent unmapped.

“This means that we lack the foundation on which to build a molecular breeding program for cannabis comparable to what exists for other crops,” said lead author Tim Sharbel, a plant scientist in the USask College of Agriculture and Bioresources. 

“Developing a high-quality genetic blueprint would provide the building blocks for genomics-based breeding and applications to human and animal health, while strengthening university-industry partnerships.

“These data are crucial for setting up a core collection of genotypes which can be used to study various cannabis traits.” 

Sharbel noted that recent societal and governmental acceptance of cannabis has spurred growing interest by companies in medical applications of cannabis use.

He is seeking medicinal plant industry partners to help fund academic research that will map, compare and make full use of the closely related genomes of cannabis, hemp, and hops. 

“This initiative would become part of an industry-driven effort to exchange resources and improve cannabis, hemp and hops for medicinal and industrial properties,” he said.

“If we can publish case studies to show that certain compounds can treat human disorders with statistical significance, then getting such information into the medicare system – for example, as a basis for a Drug Identification Number assigned to a drug product before it can be marketed in Canada – would be of great benefit to companies.” 

Prior to joining USask, Sharbel worked on medicinal plants with both academic and industry partners for 15 years in Europe, studying the effects of the German chamomile herb on digestive disorders and St. John’s wort on dementia. 

“Medicinal plants are hugely important to society, have long traditional use throughout human history, and represent important reasons to protect biodiversity. The emergence of the cannabis industry is a good driver for a larger goal of bringing traditional medicinal plants into the mainstream,” he said. 

The authors found, in the limited data that exists, support for the potential health benefits of cannabis, including treatments for pain, spasticity in multiple sclerosis, and opioid use reduction.

The analysis also cites negative short-term effects of THC, the main psychoactive compound in cannabis, such as reduced cognitive function, enhanced anxiety and fatigue, and potential long-term consequences such as permanent loss of memory, intelligence, mental focus, and judgment, as well as addiction. 

“It is critical to recognise cannabis and cannabinoids as drugs with potential benefits and associated risks, as would be the case for the investigation of any novel drug,” the authors state.

The team noted there is also evidence for developing hemp-type cannabis as a highly digestible, protein-rich food source that would be unlikely to cause an allergic reaction.